Preclinical studies, including ours, have revealed that lung cancer cells easily acquire resistance to 3rd-gen EGFR-TKIs in vitro, and some resistant cells could be clinically un-targetable, which may narrow the long-term clinical benefits of EGFR-TKIs. This evidence concerns the gene EGFR and lung cancer.